Every human is born with a spare version of hemoglobin. Fetal hemoglobin carries oxygen through the womb, then a genetic switch shuts it off in the months after birth and hands the job to the adult form. For people with sickle cell disease, that switch is a cruel bit of timing. Their adult hemoglobin is the defective kind that warps red cells into stiff crescents, jams small blood vessels, and triggers bouts of agonizing pain. The fetal version they made as infants would have worked fine.
A trial reported in the New England Journal of Medicine tries to reopen that switch. Researchers used base editing, a precise form of gene editing, to nudge patients' own blood stem cells back into making fetal hemoglobin. Among 31 people treated, not one had a severe vaso-occlusive crisis after the therapy took hold.
Editing a letter, not cutting the strand
The therapy, called risto-cel, does not slice DNA the way the original CRISPR tools do. Base editors chemically rewrite a single genetic letter in place, which the developers argue is a gentler way to change the genome. Here the target was the promoter region of the gamma-globin genes, the stretch of DNA that controls whether fetal hemoglobin gets made.
A protein called BCL11A normally clamps onto that region and keeps the fetal genes silenced. The edit changes the promoter just enough that BCL11A can no longer bind, so the fetal program switches back on. What makes this approach interesting is what it leaves alone. BCL11A itself does other important jobs in the body, and its overall expression was not changed. Only its grip on the hemoglobin switch was loosened.
Patients had their blood stem cells collected, edited in the lab, and returned by infusion after chemotherapy cleared out the old bone marrow. In the treated cells, an average of 67.4 percent of the target sites carried the intended edit at six months. That translated into blood where fetal hemoglobin made up more than 60 percent of the total, while the sickling adult form dropped below 40 percent. Those levels held throughout follow-up.
What the numbers showed
Everyone in the study had a serious history with the disease. To enroll, patients aged 12 to 35 needed at least four severe pain crises in the two years before joining. After the edited cells engrafted, the investigators reported no severe vaso-occlusive crises beginning more than 60 days after a patient's last blood transfusion. Neutrophils, a key infection-fighting cell, recovered at a median of 17.5 days, and platelets at 19 days.
That is a striking result for a condition defined by unpredictable, hospital-filling episodes. It also fits a broader wave of genetic medicines aimed at the same fetal-hemoglobin switch, including approved therapies that reach it by other routes. Base editing is one more way to arrive at the same biological destination.
Reasons to stay measured
The findings come with real limits. This was an interim look that the authors describe as unplanned, and follow-up was short: a mean of 6.6 months, with some patients tracked only a matter of weeks. A durable answer about whether crises stay away for years is not something six months can provide. The hemoglobin measurements at six months came from just 13 patients, the subset who had reached that mark.
Safety was not trivial either. Every patient had at least one adverse event, 87 percent had one graded severe or worse, and 39 percent had a serious adverse event. One patient died from idiopathic pneumonia syndrome, a known danger of the intense chemotherapy used to prepare the bone marrow. Much of that burden comes from the conditioning regimen rather than the edit itself, but it is part of the package a patient signs up for. The study was funded by Beam Therapeutics, the company developing the treatment.
What the trial establishes is narrower than a cure and more concrete than a promise. Edited stem cells engrafted, produced high levels of the protective hemoglobin, and held those levels for as long as the researchers watched. Whether that protection lasts a decade, and how the risks weigh against a lifetime of crises, will take longer trials and more patients to settle. For now, a disease caused by one misplaced genetic instruction is being answered with one deliberate correction.
Comments